Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $33.50 Average PT from Analysts
Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) have received a consensus recommendation of “Buy” from the six research firms that are covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have issued ratings on the stock in […]
More Stories
CIBC Private Wealth Group LLC Has $33,000 Stock Position in Fox Co. (NASDAQ:FOXA)
CIBC Private Wealth Group LLC increased its holdings in shares of Fox Co. (NASDAQ:FOXA – Free Report) by 122.3% during...
O Shaughnessy Asset Management LLC Sells 1,036 Shares of Qualys, Inc. (NASDAQ:QLYS)
O Shaughnessy Asset Management LLC reduced its stake in Qualys, Inc. (NASDAQ:QLYS – Free Report) by 21.2% in the fourth...
O Shaughnessy Asset Management LLC Purchases 1,308 Shares of Samsara Inc. (NYSE:IOT)
O Shaughnessy Asset Management LLC increased its stake in Samsara Inc. (NYSE:IOT – Free Report) by 11.3% in the fourth...
O Shaughnessy Asset Management LLC Purchases 1,308 Shares of Samsara Inc. (NYSE:IOT)
O Shaughnessy Asset Management LLC increased its stake in Samsara Inc. (NYSE:IOT – Free Report) by 11.3% in the fourth...
Wellington Management Group LLP Boosts Holdings in The Vita Coco Company, Inc. (NASDAQ:COCO)
Wellington Management Group LLP lifted its stake in shares of The Vita Coco Company, Inc. (NASDAQ:COCO – Free Report) by...
Wellington Management Group LLP Boosts Holdings in The Vita Coco Company, Inc. (NASDAQ:COCO)
Wellington Management Group LLP lifted its stake in shares of The Vita Coco Company, Inc. (NASDAQ:COCO – Free Report) by...